Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rohto Pharmaceutical CoRPHCF 89 Cyclically Adjusted PS Ratio is 2.24 as of Jul. 22, 2026, which is 10% below its 10-year median of 2.49. GuruFocus rates RPHCF with a GF Scoreâ„¢ of 89/100 and a GF Valueâ„¢ of $21.04. The stock has 2 warning signs investors should review. Among 1,448 Consumer Packaged Goods companies, Rohto Pharmaceutical Co ranks worse than 81.56% on this metric.
The historical rank and industry rank for Rohto Pharmaceutical Co's Cyclically Adjusted PS Ratio or its related term are showing as below:
RPHCF'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.94 Med: 2.49 Max: 4.86
Current: 2.34
During the past years, Rohto Pharmaceutical Co's highest Cyclically Adjusted PS Ratio was 4.86. The lowest was 1.94. And the median was 2.49.
RPHCF's Cyclically Adjusted PS Ratio is ranked worse than 81.56% of 1448
companies
in the Consumer Packaged Goods industry
Industry Median: 0.76
vs RPHCF: 2.34
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Rohto Pharmaceutical Co's adjusted revenue per share data for the three months ended in Mar. 2026 was $2.424. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $6.69 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Rohto Pharmaceutical Co (OTCPK:RPHCF) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Rohto Pharmaceutical Co Cyclically Adjusted PS Ratio Related Terms
Rohto Pharmaceutical Co Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Rohto Pharmaceutical Co's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rohto Pharmaceutical Co Cyclically Adjusted PS Ratio Chart
RPHCF vs PG, CL, KVUE: Cyclically Adjusted PS Ratio Comparison
For the Household & Personal Products subindustry, Rohto Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rohto Pharmaceutical Co Cyclically Adjusted PS Ratio vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Rohto Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Rohto Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.
Rohto Pharmaceutical Co Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 2.24 mean?
Rohto Pharmaceutical Co (RPHCF) has a Cyclically Adjusted PS Ratio of 2.24 as of Jul. 22, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Rohto Pharmaceutical Co and its competitors. This is 10% below median its historical median of 2.49. Over the past decade, Rohto Pharmaceutical Co's Cyclically Adjusted PS Ratio has ranged from 1.94 to 4.86. According to the industry distribution chart, Rohto Pharmaceutical Co ranks #1181 out of 1448 companies in the Consumer Packaged Goods industry, placing it in the top 81.6%.
Is Rohto Pharmaceutical Co's Cyclically Adjusted PS Ratio too high?
Rohto Pharmaceutical Co's current Cyclically Adjusted PS Ratio of 2.24 is 10% below median its 10-year median of 2.49. Over the past 10 years, this metric has ranged from a low of 1.94 to a high of 4.86. The Consumer Packaged Goods industry median Cyclically Adjusted PS Ratio is 0.76. Rohto Pharmaceutical Co's value of 2.24 is 194.7% above this industry median. Based on the distribution chart, Rohto Pharmaceutical Co ranks #1181 out of 1448 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Rohto Pharmaceutical Co has a GF Scoreâ„¢ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Rohto Pharmaceutical Co's Cyclically Adjusted PS Ratio compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Rohto Pharmaceutical Co ranks #1181 out of 1448 companies for Cyclically Adjusted PS Ratio. This places Rohto Pharmaceutical Co in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 0.76. Rohto Pharmaceutical Co's value of 2.24 is 194.7% above this benchmark. Historically, Rohto Pharmaceutical Co's own Cyclically Adjusted PS Ratio has ranged from 1.94 to 4.86 over the past decade. While the company's 10-year median is 2.49 vs. the industry median of 0.76, Rohto Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Consumer Packaged Goods company?
The median Cyclically Adjusted PS Ratio among Consumer Packaged Goods companies is 0.76, based on 1,448 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rohto Pharmaceutical Co's current Cyclically Adjusted PS Ratio of 2.24 is 194.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Rohto Pharmaceutical Co and its competitors. For the Consumer Packaged Goods industry, the median Cyclically Adjusted PS Ratio is 0.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rohto Pharmaceutical Co's current Cyclically Adjusted PS Ratio is 2.24, which is 10% below median its own 10-year median of 2.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rohto Pharmaceutical Co stock overvalued right now?
Rohto Pharmaceutical Co (RPHCF) has a current Cyclically Adjusted PS Ratio of 2.24. The stock's GF Value™ is $21.04, compared to a current price of $15.00 — trading 28.7% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 2.24, which is 10% below median its 10-year median of 2.49 and 194.7% above the Consumer Packaged Goods industry median of 0.76. Rohto Pharmaceutical Co's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Rohto Pharmaceutical Co (RPHCF), the current Cyclically Adjusted PS Ratio is 2.24 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rohto Pharmaceutical Co (RPHCF) Overvalued in 2026?
Based on GuruFocus' analysis, Rohto Pharmaceutical Co stock appears to be undervalued.
The current stock price of $15.00 is trading 28.7% below its estimated GF Value™ of $21.04.
Key valuation signals for RPHCF:
Cyclically Adjusted PS Ratio: 2.24 (10% below median its 10-year median of 2.49)
GF Value™: $21.04 vs. price of $15.00 (28.7% below fair value)
Industry Position: 194.7% above the Consumer Packaged Goods median (#1181 of 1448)
No single metric tells the full story. See the RPHCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rohto Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of health and beauty care products. The company operates through four reportable segments: Japan, America, Europe, and Asia. Each segment manufactures and sells products related to eye care (such as eye drops and eyewash), skin care (including dermatological medications, lip balm, sunscreen, and functional cosmetics), oral medication (such as gastrointestinal and herbal medicines, and supplements), and other products such as in-vitro diagnostic reagents. It generates the majority of its revenue from Japan.
89GF Score
Get the complete analysis for RPHCF
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RPHCF has been successfully added to your 
